TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives

Oncology Institute, Inc.

2024-Q2 EPS reported -$0.39 revenue$193,244,000

Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).
Gross profit $13M (-13.9%); gross margin 13.2% vs 18.8%; adjusted EBITDA ($8.7M) vs ($6.9M).
Dispensary segment revenue up 76% YoY; 10 capitation contracts signed in 2024 so far.
Company exploring strategic alternatives to maximize shareholder value.
Cash $46.4M; full year 2024 guidance updated, expecting H2 improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.